Hybrid AF Therapy (EPi-Sense)

About AtriCure

AtriCure is a publicly traded medical device company focused on developing and commercializing technologies for the interventional treatment of atrial fibrillation and post-operative pain management. The company has established itself through three synergistic platforms: Surgical Ablation, Left Atrial Appendage (LAA) Management, and Cryoanalgesia. Its strategy involves expanding the use of its therapies in both cardiac and non-cardiac surgical settings, supported by a robust clinical evidence program and a global direct sales force. Recent achievements include the launch of new products like the cryoXT probe and the initiation of the pivotal BoxX-NoAF trial to expand its addressable patient population.

Therapeutic Areas